Filing Flows › Core Scientific, Inc./tx (CORZ) › Q2 2026 › vs Q1 2026
Core Scientific, Inc./tx (CORZ) Q2 2026 vs Q1 2026 (quarter over quarter)
Core Scientific, Inc./tx's revenue rose $49.0M (+42%) from $115M in Q1 2026 to $164M in Q2 2026.
Core Scientific, Inc./tx, Q2 2026: revenue $164M (+109% year over year), operating margin -47.8%, net loss $1.2B, operating cash flow −$18.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $164M | $115M | $49.0M | +42% |
| Net loss | $1.2B | $347M | $808M | +233% |
| Costs & expenses | $1.3B | $462M | $857M | +185% |
| Operating costs | $243M | $426M | −$183M | -43% |
| Interest & other, net | $1.1B | $36.2M | $1.0B | 30× |
| Income tax | $1.9M | $600K | $1.3M | +218% |
| Cost of revenue | $94.2M | $85.1M | $9.0M | +11% |
| SG&A | $49.4M | $44.8M | $4.5M | +10% |
| Other operating costs | $99.1M | $296M | −$197M | -66% |
| Operating cash sources | $1.2B | $347M | $808M | +233% |
| Depreciation & amortization | $15.5M | $16.6M | −$1.1M | -7% |
| Share-based compensation | $18.2M | $17.8M | $479K | +3% |
| Working capital & other | $1.1B | $563M | $540M | +96% |
| Cash used in operations | $18.9M | −$250M | $269M | — |
| Net loss absorbed | $1.2B | $347M | $808M | +233% |
Questions
How much did Core Scientific, Inc./tx's revenue grow quarter over quarter in Q2 2026?
Core Scientific, Inc./tx's revenue rose $49.0M (+42%) from $115M in Q1 2026 to $164M in Q2 2026.